- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT00226577
Pharmacogenomic & Phase II Study of Gemcitabine and Pemetrexed in Non-Small-Cell Lung Cancer.
Phase II Study of Neoadjuvant Chemotherapy With Gemcitabine and Pemetrexed in Resectable Non-Small-Cell Lung Cancer (NSCLC) With Pharmacogenomic Correlates.
Tutkimuksen yleiskatsaus
Tila
Ehdot
Interventio / Hoito
Yksityiskohtainen kuvaus
This study will evaluate the efficacy and safety of neoadjuvant chemotherapy with gemcitabine and pemetrexed given together 4-times biweekly in patients with resectable NSCLC. All patients will be seen by members of the Thoracic Oncology Program at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida, and they will be discussed in our weekly multidisciplinary thoracic oncology conference. The conference includes pathologists, radiologists, thoracic surgeons, pulmonologists, radiation oncologists, medical oncologists, oncology nurse specialists, case managers, social workers, and clinical trials coordinators. They will have initial tests as outlined in the study timetable. Patients will receive gemcitabine biweekly on days 1, 15, 29, and 43 at a dose of 1,500 mg/m2. They will also receive pemetrexed at a dose of 500 mg/m2 on days 1, 15, 29, and 43. Gemcitabine will be given first over a period of 30 minutes i.v. followed by pemetrexed over 10 minutes i.v. All patients will get a post induction chemotherapy PET scan, CT scan, and PFT's including a DLCO. They will then go on to thoracotomy including bronchoscopy and mediastinal lymph node dissection between days 64 and 77 if the tumor is deemed completely resectable on restaging studies.
The administration of chemotherapy at the earliest time (neoadjuvant or induction chemotherapy) following diagnosis in an effort to reduce the risk of disease recurrence. This approach also allows for investigations of molecular parameters that may affect response to chemotherapy and patients' survival. It is our hypothesis that the expression of genes associated with activation, inactivation, and efficacy of the drugs gemcitabine and pemetrexed will predict response to therapy and prognosis. We further hypothesize that the expression of these genes will be altered during chemotherapy, and that the global assessment of tumor proliferation, apoptosis, and genome damage is associated with response to therapy. We propose a phase II study of neoadjuvant chemotherapy with gemcitabine and pemetrexed in patients with resectable NSCLC, specifically correlating molecular and genetic parameters to the primary clinical study endpoint disease response (radiographic CR+PR) and the secondary endpoints complete pathological response at surgery, disease-free survival, and overall survival.
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Vaihe 2
Yhteystiedot ja paikat
Opiskelupaikat
-
-
Florida
-
Tampa, Florida, Yhdysvallat, 33612
- H. Lee Moffitt Cancer Center & Research Institute
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Microscopically confirmed non-small cell carcinoma of the lung, which may be confirmed at the initial bronchoscopy and mediastinoscopy, or by transthoracic needle biopsy.
- No prior therapy for lung cancer.
- Patients must have disease stages IB (T2N0M0), IIA (T1N1M0), IIB (T2N1M0 and T3N0M0), or IIIA (T3N1M0 and T1-3N2M0). Patients with 2 lesions in one lobe (T4) (Stage IIIB) are eligible.
- Patients must be deemed medically fit for surgical resection by a thoracic surgeon.
- Patients must have an ECOG performance status of Zero or One.
- Patients must have measurable or evaluable disease.
- Measurable Disease: Any mass reproducibly measurable in one diameter (RECIST criteria).
- Evaluable disease: Lesions apparent on chest CT, which do not meet the criteria for measurability. These include ill-defined masses associated with post obstructive changes.
- Age >18 years.
- Patient must be able to understand and sign the informed consent.
- Patients must be >12 weeks from prior major surgery, such as a coronary artery bypass graft.
Exclusion Criteria:
- White blood cell count <3000/mm3
- Platelet count <100,000/mm3
- Hemoglobin <9.0 g/dl
- Creatinine >1.5 mg/dl
- Total bilirubin >1.5 mg/dl
- SGOT, SGPT, or AP >1.5 x upper limit of normal
- Metastatic disease (except peribronchial/hilar lymph nodes=N1 and ipsilateral/subcarinal mediastinal lymph nodes=N2) or malignant pleural effusion detected on preoperative evaluation. Non-malignant effusions are cytology negative, are non-bloody, and are transudates. Effusions visible only on CT and not large enough for safe thoracentesis will not result in ineligibility. Exudative effusions, even if cytologically negative are excluded. Pleural fluid is considered exudative if: the ratio of pleural fluid protein to serum protein is >0.5 or the ratio of pleural fluid LDH to serum to serum LDH >0.6 or Pleural fluid LDH is >200 IU/liter. A staging PET scan will be used to exclude patients. If there are multiple areas of FDG uptake outside the area of the primary tumor and the hilar and ipsilateral mediastinal lymph nodes, the patient will be excluded by virtue of having metastatic disease. If however, only one area shows an increase in FDG uptake, the area of concern will need further evaluation such as a biopsy to exclude metastatic disease.
- N3 lymph nodes (contralateral mediastinal/hilar and supraclavicular/scalene) or T4 primary tumor (malignant pleural effusion or mediastinal invasion) by clinical staging criteria (N3 as seen on CT or PET scan, which may be proven by mediastinoscopy at the investigators discretion).
- Pregnancy.
- Other active malignancy within 2 years with the exceptions of non-melanoma skin cancer and cervical carcinoma in situ.
- Psychologic, familial, sociologic, or geographic conditions, which do not permit biweekly medical follow-up and adherence to the study protocol.
- Prior radiation therapy for any cancer to the thorax.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei käytössä
- Inventiomalli: Yksittäinen ryhmätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
---|---|
Kokeellinen: Pre-Surgery Chemotherapy
|
Gemcitabine (GemzarR) 1500 mg/m2
Muut nimet:
Pemetrexed (AlimtaR) 500 mg/m2
Muut nimet:
When the chemotherapy treatment is completed, the patient's tumor response will be evaluated by a CT scan, pulmonary function test, and another PET scan between days 50 and 63 (during weeks 8 and 9).
If there is no growth or spread of the cancer on any of these tests, patients will then proceed to have surgery by week 10 to remove the cancer.
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Disease Response - Radiographic
Aikaikkuna: 06/20/2008 Index date for patients enrolled between 04/2004 and 04/2006
|
Number of participants with partial or Complete Response. Complete response (CR) is defined as the total disappearance of all malignant and evaluable clinical evidence of cancer without the development of any new malignant lesions documented on the post chemotherapy chest CT and PET scan. Partial response (PR) (measurable disease only): When compared with pre-treatment measurements, a reduction of >30% in the sum of the largest diameters of all measurable lesions and absence of new lesions. |
06/20/2008 Index date for patients enrolled between 04/2004 and 04/2006
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Disease Response - Pathologic
Aikaikkuna: 06/20/2008 Index date for patients enrolled between 04/2004 and 04/2006
|
Number of participants with Pathologic Complete Response.
Pathologic complete response (pCR) is defined by a surgical pathology specimen, which consists of equal to or more than 95% fibrosis and necrosis.
|
06/20/2008 Index date for patients enrolled between 04/2004 and 04/2006
|
Survival - Disease Free
Aikaikkuna: 06/20/2008 Index date for patients enrolled between 04/2004 and 04/2006
|
Disease-free survival (DFS) is defined as the period of time from surgery to the time when disease recurrence is clearly documented.
A histologic confirmation is required in equivalent cases.
|
06/20/2008 Index date for patients enrolled between 04/2004 and 04/2006
|
Survival - Overall
Aikaikkuna: 06/20/2008 Index date for patients enrolled between 04/2004 and 04/2006
|
Median range of number of participants with Overall Survival.
Overall survival (OS) will be defined as the period of time from the first day of drug treatment to the date of death of the patient.
Patients taken off study will be followed quarterly until death for survival data.
|
06/20/2008 Index date for patients enrolled between 04/2004 and 04/2006
|
Toxicity
Aikaikkuna: 06/20/2008 Index date for patients enrolled between 04/2004 and 04/2006
|
Number of participants with toxicity ≥ Grade 3 after gemcitabine plus pemetrexed induction chemotherapy.
|
06/20/2008 Index date for patients enrolled between 04/2004 and 04/2006
|
Yhteistyökumppanit ja tutkijat
Tutkijat
- Päätutkija: Gerold Bepler, M.D, Ph.D., H. Lee Moffitt Cancer Center (now at Karmanos Cancer Institute)
Julkaisuja ja hyödyllisiä linkkejä
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Arvio)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
- Hengityselinten sairaudet
- Neoplasmat
- Keuhkosairaudet
- Neoplasmat sivustoittain
- Hengitysteiden kasvaimet
- Rintakehän kasvaimet
- Syöpä, bronkogeeninen
- Keuhkoputkien kasvaimet
- Keuhkojen kasvaimet
- Karsinooma, ei-pienisoluinen keuhko
- Huumeiden fysiologiset vaikutukset
- Farmakologisen vaikutuksen molekyylimekanismit
- Infektiota estävät aineet
- Viruksenvastaiset aineet
- Nukleiinihapposynteesin estäjät
- Entsyymin estäjät
- Antimetaboliitit, antineoplastiset
- Antimetaboliitit
- Antineoplastiset aineet
- Immunosuppressiiviset aineet
- Immunologiset tekijät
- Foolihappoantagonistit
- Gemsitabiini
- Pemetreksedi
Muut tutkimustunnusnumerot
- MCC-13726
- H3E-US-X009 (Muu tunniste: Eli Lilly & Company)
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Keuhkosyöpä
-
Jonsson Comprehensive Cancer CenterEli Lilly and Company; Genentech, Inc.Aktiivinen, ei rekrytointiMetastaattinen keuhkojen ei-pienisolusyöpä | Tulenkestävä keuhkojen ei-pienisolusyöpä | Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8 | Stage IVA Lung Cancer AJCC v8 | Vaihe IVB keuhkosyöpä AJCC v8Yhdysvallat
-
Mansoura UniversityRekrytointi
-
University of Southern CaliforniaNational Cancer Institute (NCI); Genentech, Inc.RekrytointiStage IVA Lung Cancer AJCC v8 | Vaihe IVB keuhkosyöpä AJCC v8 | Keuhkojen ei-pienisolukarsinooma | Vaiheen III keuhkosyöpä AJCC v8 | IV vaiheen keuhkosyöpä AJCC v8 | Vaiheen II keuhkosyöpä AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Vaiheen IIB keuhkosyöpä AJCC v8 | Vaiheen IIIA keuhkosyöpä AJCC v8 | Vaiheen IIIB... ja muut ehdotYhdysvallat
-
Philipps University Marburg Medical CenterAktiivinen, ei rekrytointiTransplantation LungItävalta, Saksa
-
The University of Hong KongRekrytointi
-
University of Sao Paulo General HospitalRekrytointi
-
Centre Hospitalier Universitaire de BesanconBiothelisTuntematonSydänkirurgia | Kardiopulmonaalinen ohitus | Lung
-
Eben RosenthalRekrytointiStage IVA Lung Cancer AJCC v8 | Vaihe IVB keuhkosyöpä AJCC v8 | IV vaiheen keuhkosyöpä AJCC v8 | Keuhkokarsinooma | Metastaattinen pahanlaatuinen kasvain keuhkoissaYhdysvallat
-
Kasr El Aini HospitalValmisExta Vascular Lung WaterEgypti
-
National Cancer Institute (NCI)ValmisLung | Aivot | Rinta | Eturauhanen | EndometriumYhdysvallat